11C-methionine(11C-methionine) - 在研适应症：室管膜瘤，颅咽管瘤_专利_临床

概要

基本信息

药物类型

小分子化药

别名-

靶点-

作用机制

PET imaging(正电子发射断层成像术增强剂)

治疗领域

肿瘤神经系统疾病其他疾病

在研适应症

室管膜瘤颅咽管瘤

非在研适应症-

原研机构

St. Jude Children's Research Hospital, Inc.

在研机构

St. Jude Children's Research Hospital, Inc.

非在研机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

17

项与 11C-methionine 相关的临床试验

EUCTR2020-000640-64-CZ

/ Not yet recruiting临床2期IIT

11C-METHIONIN IN DIAGNOSIS AND MANAGEMENT OF PATIENTS WITH AGGRESSIVE GLIOBLASTOM SHOWING A TIME POST-OPERATING PROGRESS BEFORE INITIATING ADJUVANT ONCOLOGICAL TREATMENT - GlioMET

开始日期2020-05-26

申办/合作机构-

NCT05608395

/ Active, not recruiting临床2期IIT

11C-methionine in Diagnostics and Management of Glioblastoma Multiforme With Rapid Early Progression Patients Prior to Adjuvant Oncological Therapy (GlioMET)

Glioblastoma multiforme (GBM) is the most common primary brain cancer. The treatment of GBM consists of a combination of surgery and subsequent oncological therapy, i.e. radiotherapy, chemotherapy, or combination of both at te same time. If post-operative oncological therapy involves irradiation, magnetic resonance imaging (MRI) is planned. Unfortunately, in some cases, a very early worsening (progression) or return (recurrence) of the disease is observed several weeks after the surgery, i.e. rapid early progression (REP). Radiotherapy planning is based on this MRI in all patients. However, a subset of patients with REP have a less favorable prognosis with this treatment management. The investigators therefore assume that these patients need a more thorough examination to form a precise radiotherapy plan. The project focuses on this group of patients with a less favorable prognosis (with a more aggressive disease). Patients who develop REP within approximately 6 weeks after surgery will have PET/CT (positron emission tomography in combination with computed tomography) examinations using the radiopharmaceutical 11C-methionine in addition to standard practice. PET is one of the most modern methods of molecular imaging, a non-invasive in vivo method that allows physicians to study processes in the human body using radiolabeled radiopharmaceuticals. 11C-methionine is an example of a radiolabeled (carbon 11) amino acid - a source of energy for tumor cells and a building material for new proteins. This radiopharmaceutical is commonly used in the diagnosis of brain tumors and in the evaluation of response to treatment. For patients who undergo this examination, the radiotherapy planning will be adjusted based on it. The purpose of clinical trial is to improve the prospects of patients with REP.

开始日期2020-05-01

申办/合作机构

Masaryk Memorial Cancer Institute

JPRN-UMIN000037036

/ RecruitingN/AIIT

Study to investigate growth style of brain tumor using 11C-methionine PET - Study to investigate growth style of brain tumor using 11C-methionine PET

开始日期2019-06-12

申办/合作机构-

100 项与 11C-methionine 相关的临床结果

登录后查看更多信息

100 项与 11C-methionine 相关的转化医学

登录后查看更多信息

100 项与 11C-methionine 相关的专利（医药）

登录后查看更多信息

98

项与 11C-methionine 相关的文献（医药）

2024-06-01·Cancer biotherapy & radiopharmaceuticals

Evaluating the Diagnostic Efficacy of ^99mTc-Methionine Single-Photon Emission Computed Tomography–Computed Tomography: A Head-to-Head Comparison with ¹¹C-Methionine Positron Emission Tomography–Magnetic Resonance Imaging in Glioma Patients

Article

作者: Saini, Jitender ; Sitani, Keerti ; Sadashiva, Nishanth ; Beniwal, Manish ; Basavaraja, Harish ; Mishra, Anil Kumar ; Mangalore, Sandhya ; Rajan, Archith ; Nagaraj, Chandana ; Kumar, Aishwarya ; Santosh, Vani ; Kumar, Pardeep ; Hazari, Puja Panwar

Background: Amino acid positron emission tomography (PET) imaging plays a significant role in the diagnosis of gliomas and in differentiating tumor recurrence from necrosis. In this study, the authors evaluated the diagnostic efficacy of [^99mTc]Tc-methionine single-photon emission computed tomography-computed tomography (SPECT-CT) in comparison with [¹¹C]methionine PET-magnetic resonance imaging (MRI) in delineating tumors. Methods: Thirty-one (primary: 16 and postoperative: 15) patients of confirmed (either MRI or histopathological proven) glioma underwent both [^99mTc]Tc-methionine SPECT-CT and [¹¹C]methionine PET-MRI. A comparative analysis was performed between SPECT, PET, and MR images to calculate the concordance between the modalities and to evaluate the diagnostic efficacy of the [^99mTc]Tc-methionine SPECT. Results: [^99mTc]Tc-methionine SPECT showed comparable uptake in the tumor lesions in comparison to [¹¹C]methionine PET. A significant and strong positive correlation was observed between the volume of tumor (Vt) in PET and Vt MR (p < 0.004). Likewise, a significant and strong positive correlation was found between Vt SPECT and Vt MR. [^99mTc]-methionine has a sensitivity and specificity of 91% and 75%, respectively, compared with 82% and 100% for [¹¹C]methionine in postoperative cases to differentiate the tumor recurrence from necrosis. The sensitivity and specificity of [^99mTc]Tc-methionine was 92% and 100%, respectively, compared with 92% and 67% for [¹¹C]methionine in primary tumors. Conclusion: [^99mTc]Tc-methionine SPECT-CT is as equally good as [¹¹C]methionine for diagnosing and differentiating it from necrosis especially in high-grade glioma.

2023-08-01·Journal of neuro-oncology

T2-FLAIR mismatch sign correlates with ¹¹C-methionine uptake in lower-grade diffuse gliomas.

Article

作者: Nariai, Tadashi ; Ebiko, Yusuke ; Maehara, Taketoshi ; Tamura, Kaoru ; Hara, Shoko ; Ishii, Kenji ; Tanaka, Yoji ; Inaji, Motoki

PURPOSE:

The T2-FLAIR mismatch sign is recognized as an imaging finding highly suggestive of IDH-mutant astrocytomas. This study was designed to determine whether the T2-FLAIR mismatch sign correlates with uptake of ¹¹C-methionine in lower-grade gliomas.

METHODS:

We included 78 histopathologically verified lower-grade gliomas (grade 2: 31 cases, grade 3: 47 cases) in this study. 78 patients underwent ¹¹C-methionine positron emission tomography (MET-PET) scans and magnetic resonance (MR) imaging scans prior to histological diagnosis. The tumor-to-normal ratio (T/N) of ¹¹C-methionine uptake was calculated by dividing the maximum standardized uptake value (SUV) for the tumor by the mean SUV of the normal brain. MR imaging scans were evaluated for the presence of the T2-FLAIR mismatch sign by three independent reviewers. We compared molecular status, the T2-FLAIR mismatch sign and ¹¹C-methionine uptake among patients with different lower-grade glioma molecular types.

RESULTS:

The 78 lower-grade gliomas were assigned to one of three molecular groups: Group A (IDH-mutant and 1p/19q non-codeleted, n = 22), Group O (IDH-mutant and 1p/19q codeleted, n = 20), and Group W (IDH wildtype, n = 36). T2-FLAIR mismatch was found in 16 cases (20.5%) that were comprised of 8 (36.4%), 0 (0%), 8 (22.2%) cases in the molecular group A, O and W, respectively. The median T/N ratio of MET-PET in tumors with T2-FLAIR mismatch was 1.50, which was significantly lower than that of tumors without T2-FLAIR mismatch (1.83, p < 0.001, Mann-Whitney U test). In the Groups A and W (excluding Group O), the median T/N ratio on MET-PET in groups A and W (but not group O) with T2-FLAIR mismatch was 1.50, which was significantly lower than that of tumors without T2-FLAIR mismatch (1.81, p = 0.002, Mann-Whitney U test).

CONCLUSION:

The T2-FLAIR mismatch sign correlated with lower ¹¹C-methionine uptake in lower grade gliomas.

2023-06-01·EJNMMI physics

Development of a bespoke phantom to optimize molecular PET imaging of pituitary tumors.

Article

作者: Marsden, Daniel ; Santarius, Thomas ; MacFarlane, James ; Harper, Ines ; Gillett, Daniel ; van der Meulen, Merel ; Koulouri, Olympia ; Bird, Nick ; Aloj, Luigi ; Cheow, Heok ; Crawford, Rosy ; Heard, Sarah ; Mendichovszky, Iosif A ; Bashari, Waiel ; Mannion, Richard ; Ballout, Safia ; Powlson, Andrew S ; Gillett, Bethany ; Gurnell, Mark ; Kolias, Angelos

BACKGROUND:

Image optimization is a key step in clinical nuclear medicine, and phantoms play an essential role in this process. However, most phantoms do not accurately reflect the complexity of human anatomy, and this presents a particular challenge when imaging endocrine glands to detect small (often subcentimeter) tumors. To address this, we developed a novel phantom for optimization of positron emission tomography (PET) imaging of the human pituitary gland. Using radioactive 3D printing, phantoms were created which mimicked the distribution of ¹¹C-methionine in normal pituitary tissue and in a small tumor embedded in the gland (i.e., with no inactive boundary, thereby reproducing the in vivo situation). In addition, an anatomical phantom, replicating key surrounding structures [based on computed tomography (CT) images from an actual patient], was created using material extrusion 3D printing with specialized filaments that approximated the attenuation properties of bone and soft tissue.

RESULTS:

The phantom enabled us to replicate pituitary glands harboring tumors of varying sizes (2, 4 and 6 mm diameters) and differing radioactive concentrations (2 ×, 5 × and 8 × the normal gland). The anatomical phantom successfully approximated the attenuation properties of surrounding bone and soft tissue. Two iterative reconstruction algorithms [ordered subset expectation maximization (OSEM); Bayesian penalized likelihood (BPL)] with a range of reconstruction parameters (e.g., 3, 5, 7 and 9 OSEM iterations with 24 subsets; BPL regularization parameter (β) from 50 to 1000) were tested. Images were analyzed quantitatively and qualitatively by eight expert readers. Quantitatively, signal was the highest using BPL with β = 50; noise was the lowest using BPL with β = 1000; contrast was the highest using BPL with β = 100. The qualitative review found that accuracy and confidence were the highest when using BPL with β = 400.

CONCLUSIONS:

The development of a bespoke phantom has allowed the identification of optimal parameters for molecular pituitary imaging: BPL reconstruction with TOF, PSF correction and a β value of 400; in addition, for small (< 4 mm) tumors with low contrast (2:1 or 5:1), sensitivity may be improved using a β value of 100. Together, these findings should increase tumor detection and confidence in reporting scans.

100 项与 11C-methionine 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
室管膜瘤	临床2期	美国	St. Jude Children's Research Hospital, Inc.	2014-05-07
颅咽管瘤	临床2期	美国	St. Jude Children's Research Hospital, Inc.	2011-08-22

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


EANM2022	N/A	胶质瘤	21	[99mTc] methionine	範鑰構鏇夢積鹹鏇餘積(齋顧襯顧夢壓淵鹽遞鬱) = 積壓夢衊網觸鏇衊選鑰遞遞鏇壓顧憲鹽蓋醖壓 (鬱範齋網夢壓蓋積壓選 ) 更多	-	2022-09-22
				[11C] methionine	範鑰構鏇夢積鹹鏇餘積(齋顧襯顧夢壓淵鹽遞鬱) = 壓製鹹觸顧衊遞醖糧齋遞遞鏇壓顧憲鹽蓋醖壓 (鬱範齋網夢壓蓋積壓選 ) 更多
SNMMI2022	N/A	多发性骨髓瘤	-	11C-Methionine (MM patients)	餘製壓淵鑰顧淵膚顧齋(鏇憲網製襯鏇廠蓋鏇獵) = 鏇艱鹽淵繭築繭憲願遞繭構窪艱夢窪鹹糧蓋鏇 (觸獵膚築遞鑰獵蓋簾積, 6.6)	-	2022-08-08
				11C-Methionine (Controls)	餘製壓淵鑰顧淵膚顧齋(鏇憲網製襯鏇廠蓋鏇獵) = 夢鬱膚糧淵膚齋範衊網繭構窪艱夢窪鹹糧蓋鏇 (觸獵膚築遞鑰獵蓋簾積, 0.8)
EANM2021	N/A	胶质瘤 IDH-mutant \| IDH-wildtype	201	11 C-methionine (PET-positive patients)	醖製鏇觸醖憲廠鹽鹽顧(淵淵獵鬱艱糧簾遞醖蓋) = 糧衊壓窪憲醖齋製襯遞選鑰蓋構壓簾齋廠壓構 (窪憲鏇繭窪願鬱齋觸鬱 )	-	2021-09-24
				11 C-methionine (PET-negative patients)	醖製鏇觸醖憲廠鹽鹽顧(淵淵獵鬱艱糧簾遞醖蓋) = 醖餘窪網窪鹽窪鏇襯鏇選鑰蓋構壓簾齋廠壓構 (窪憲鏇繭窪願鬱齋觸鬱 )
EANM2020	N/A	可见病灶 11C-Methionine \| perfusion weighted imaging (PWI)	10	11C-Methionine (Perfusion Weighted Imaging (PWI))	襯齋鏇艱鹽壓製淵艱淵(蓋淵範鑰鹽壓簾鑰鏇觸) = mean DICE index between PET and Gd-VOIs of the lesions was moderate (0.58 ± 0.15) 簾顧淵觸範簾糧夢餘築 (選鹽網襯鹹廠網鬱構鹹 ) 更多	-	2020-09-18
ASTRO	N/A	胶质母细胞瘤	-	(11)C-Methionine (11C-methionine (MET)-PET)	艱製鏇製憲製製膚鏇觸(築鹹鬱積鑰壓鹽淵鏇夢) = 蓋醖蓋窪淵夢糧鑰獵顧蓋鏇鹹齋製膚襯鹽壓鏇 (願淵衊製蓋憲築選窪積, 0 ~ 43.8)	-	2019-09-01
SNMMI2018	N/A	辐射损伤 \| 脑癌	-	11C-methionine (Brain Tumor Recurrence)	顧鬱積醖艱築範襯糧鬱(壓蓋鑰糧鏇鬱憲願繭獵) = 醖鏇遞壓醖築襯壓觸網構構獵壓襯觸顧築簾膚 (遞築築鏇夢壓築網鑰夢, 0.15)	-	2018-05-23
				11C-methionine (Radiation Necrosis)	顧鬱積醖艱築範襯糧鬱(壓蓋鑰糧鏇鬱憲願繭獵) = 簾膚餘遞範鏇獵夢鬱衊構構獵壓襯觸顧築簾膚 (遞築築鏇夢壓築網鑰夢, 0.22)
11 C-Methionine PET Examination (SNMMI2018)	N/A	胶质瘤 isocitrate dehydrogenase 1-R132H mutational status (IDH1-R132H)	160	11 C-Methionine (Male patients)	積積憲積鹹齋鬱夢積鬱(衊窪襯艱壓積鏇範製願) = 壓鏇廠夢餘齋繭製醖遞製糧繭衊顧餘顧獵獵壓 (鬱選襯鏇製窪觸鏇遞廠 )	-	2018-05-23
				11 C-Methionine (Female patients)	積積憲積鹹齋鬱夢積鬱(衊窪襯艱壓積鏇範製願) = 襯觸築鏇醖餘獵構蓋廠製糧繭衊顧餘顧獵獵壓 (鬱選襯鏇製窪觸鏇遞廠 )
EANM2017	N/A	原发性甲状旁腺功能亢进症	-	99m Tc-MIBI	鏇壓鏇範鑰鬱願襯醖範(鏇獵蓋齋觸繭鑰遞選糧) = 鏇齋構壓製顧願築積憲鑰廠衊獵顧獵繭齋衊廠 (鑰廠選築鏇膚餘選醖壓 ) 更多	-	2017-09-11
EANM2016	N/A	MET PET	160	[11C]Methionine PET	壓願憲獵淵築廠蓋鏇壓(餘艱顧膚衊範構衊顧廠) = 網獵憲鏇齋鏇醖窪遞範艱鏇構淵築簾蓋構膚構 (醖範簾願鹽鏇壓窪鏇艱, 15)	-	2016-09-21
EANM2016	N/A	多发性骨髓瘤	26	11C-Methionine18FDGethionine (18FDG PET/CT)	獵鹽繭襯繭鑰壓鏇蓋製(壓餘構簾網蓋鹽窪鏇觸) = 鹹鏇築壓膚網獵遞襯糧製膚築餘齋鬱餘壓衊繭 (鏇淵顧餘艱鹹鏇鬱製窪 )	积极	2016-09-21